{"id":"ly2189265","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, contributing to weight loss. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.","oneSentence":"LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:53.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06739122","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-01-10","conditions":"Type 2 Diabetes","enrollment":55},{"nctId":"NCT07313813","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":20},{"nctId":"NCT04255433","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":13299},{"nctId":"NCT05564039","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-30","conditions":"Type 2 Diabetes","enrollment":282},{"nctId":"NCT05659537","phase":"PHASE4","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-12-29","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT04515576","phase":"PHASE1","title":"A Study of LY3493269 in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-25","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT04809220","phase":"PHASE3","title":"A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":591},{"nctId":"NCT05377333","phase":"PHASE1","title":"A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT04591626","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02963766","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-12-29","conditions":"Type 2 Diabetes","enrollment":154},{"nctId":"NCT03861052","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-07","conditions":"Type 2 Diabetes","enrollment":636},{"nctId":"NCT04641312","phase":"PHASE1","title":"A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-25","conditions":"Healthy, Type 2 Diabetes","enrollment":67},{"nctId":"NCT04143802","phase":"PHASE1","title":"A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-18","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT02597049","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":424},{"nctId":"NCT03495102","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-04-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1842},{"nctId":"NCT01394952","phase":"PHASE3","title":"Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-07-22","conditions":"Cardiovascular Disease, Diabetes Mellitus, Type 2","enrollment":9901},{"nctId":"NCT02152371","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT02750410","phase":"PHASE4","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-08","conditions":"Type 2 Diabetes","enrollment":159},{"nctId":"NCT02973100","phase":"PHASE2","title":"A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-12","conditions":"Type 2 Diabetes","enrollment":318},{"nctId":"NCT01621178","phase":"PHASE3","title":"A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes, Chronic Kidney Disease","enrollment":577},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT01644500","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":737},{"nctId":"NCT03315780","phase":"PHASE4","title":"A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-28","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT03131687","phase":"PHASE2","title":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-05-24","conditions":"Type 2 Diabetes Mellitus","enrollment":318},{"nctId":"NCT03363906","phase":"PHASE1","title":"A Study of Dulaglutide in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-07","conditions":"Healthy","enrollment":27},{"nctId":"NCT01667900","phase":"PHASE1","title":"A Study of Dulaglutide in Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-08","conditions":"Diabetes Mellitus, Type 2, Healthy Volunteers","enrollment":58},{"nctId":"NCT01769378","phase":"PHASE3","title":"Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT01001104","phase":"PHASE2","title":"A Study of LY2189265 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01558271","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00734474","phase":"PHASE2, PHASE3","title":"A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1202},{"nctId":"NCT01149421","phase":"PHASE2","title":"A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT01468181","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":394},{"nctId":"NCT01064687","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":978},{"nctId":"NCT01075282","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":810},{"nctId":"NCT01126580","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":807},{"nctId":"NCT00791479","phase":"PHASE2","title":"Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":167},{"nctId":"NCT00630825","phase":"PHASE2","title":"A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus Type 2","enrollment":262},{"nctId":"NCT01524770","phase":"PHASE1","title":"A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT01624259","phase":"PHASE3","title":"A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":599},{"nctId":"NCT01458210","phase":"PHASE1","title":"A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT01191268","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 2","enrollment":884},{"nctId":"NCT01324388","phase":"PHASE1","title":"A Study of the Effect of LY2189265 on Two Blood Pressure Drugs","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Diabetes Mellitus, Type 2","enrollment":51},{"nctId":"NCT01250834","phase":"PHASE1","title":"LY2189265 and Atorvastatin Interaction Study","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT01408888","phase":"PHASE1","title":"A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01300260","phase":"PHASE1","title":"Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01215968","phase":"PHASE1","title":"A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":38},{"nctId":"NCT01432938","phase":"PHASE1","title":"A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":28},{"nctId":"NCT01253304","phase":"PHASE1","title":"A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT01436201","phase":"PHASE1","title":"A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01301092","phase":"PHASE1","title":"A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type II","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dulaglutide","Trulicity","dulaglutide"],"phase":"phase_3","status":"active","brandName":"LY2189265","genericName":"LY2189265","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}